Literature DB >> 12829593

Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia.

Anthony V Moorman1, Sue M Richards, Mary Martineau, Kan Luk Cheung, Hazel M Robinson, G Reza Jalali, Zoe J Broadfield, Rachel L Harris, Kerry E Taylor, Brenda E S Gibson, Ian M Hann, Frank G H Hill, Sally E Kinsey, Tim O B Eden, Christopher D Mitchell, Christine J Harrison.   

Abstract

High hyperdiploidy (HeH) (51 to 65 chromosomes) is found in one third of children with acute lymphoblastic leukemia and is associated with a good prognosis. Cytogenetic features may further refine this prognosis and identify patients with a poor outcome. We examined the effect of sex, age, individual trisomies, modal number, and structural abnormalities on survival among 700 children with HeH. Univariate analysis showed that age. sex, +4, +10, +18, and a high modal number were associated with survival. Multivariate analysis however, revealed that only age, sex, +4, and +18 were independent indicators. Hazard scores for predicting relapse and mortality were constructed. Three risk groups with 5-year event-free survival (EFS) rates of 86%, 75%, and 50% (P <.0001) were identified. The high-risk group comprised boys older than 9 years, boys aged 1 through 9 years without +18, and girls older than 9 years without +18, while girls aged 1 through 9 years with +18 had the best EFS. In terms of mortality, those younger than age 10 years with both +4 and +18 had an improved survival (96% vs 84% at 5 years, P <.0001). These findings confirm that the outcome of children with HeH is heterogeneous and that specific trisomies can identify patients with the greatest and least risk of treatment failure.

Entities:  

Mesh:

Year:  2003        PMID: 12829593     DOI: 10.1182/blood-2003-04-1128

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Kajsa Paulsson; Erik Forestier; Henrik Lilljebjörn; Jesper Heldrup; Mikael Behrendtz; Bryan D Young; Bertil Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 2.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

3.  Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Authors:  Marie-Lorraine Chretien; Jill Corre; Valerie Lauwers-Cances; Florence Magrangeas; Alice Cleynen; Edwige Yon; Cyrille Hulin; Xavier Leleu; Frederique Orsini-Piocelle; Jean-Sebastien Blade; Claudine Sohn; Lionel Karlin; Xavier Delbrel; Benjamin Hebraud; Murielle Roussel; Gerald Marit; Laurent Garderet; Mohamad Mohty; Philippe Rodon; Laurent Voillat; Bruno Royer; Arnaud Jaccard; Karim Belhadj; Jean Fontan; Denis Caillot; Anne-Marie Stoppa; Michel Attal; Thierry Facon; Philippe Moreau; Stephane Minvielle; Hervé Avet-Loiseau
Journal:  Blood       Date:  2015-10-29       Impact factor: 22.113

Review 4.  Molecular cytogenetics in haematological malignancy: current technology and future prospects.

Authors:  Lyndal Kearney; Sharon W Horsley
Journal:  Chromosoma       Date:  2005-10-15       Impact factor: 4.316

Review 5.  Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.

Authors:  Eric S Schafer; Stephen P Hunger
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

6.  Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.

Authors:  James B Nachman; Nyla A Heerema; Harland Sather; Bruce Camitta; Erik Forestier; Christine J Harrison; Nicole Dastugue; Martin Schrappe; Ching-Hon Pui; Giuseppe Basso; Lewis B Silverman; Gritta E Janka-Schaub
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

Review 7.  Cytogenetics and molecular genetics of acute lymphoblastic leukemia.

Authors:  Krzysztof Mrózek; David P Harper; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

8.  Evolutionary trajectories of hyperdiploid ALL in monozygotic twins.

Authors:  C M Bateman; D Alpar; A M Ford; S M Colman; D Wren; M Morgan; L Kearney; M Greaves
Journal:  Leukemia       Date:  2014-06-04       Impact factor: 11.528

Review 9.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.

Authors:  Anthony V Moorman
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941

10.  Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.

Authors:  N Gefen; V Binder; M Zaliova; Y Linka; M Morrow; A Novosel; L Edry; L Hertzberg; N Shomron; O Williams; J Trka; A Borkhardt; S Izraeli
Journal:  Leukemia       Date:  2009-11-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.